Most antidepressants aren’t helping young people with their mental health, say experts

&Tab;&Tab;<div class&equals;"wpcnt">&NewLine;&Tab;&Tab;&Tab;<div class&equals;"wpa">&NewLine;&Tab;&Tab;&Tab;&Tab;<span class&equals;"wpa-about">Advertisements<&sol;span>&NewLine;&Tab;&Tab;&Tab;&Tab;<div class&equals;"u top&lowbar;amp">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;<amp-ad width&equals;"300" height&equals;"265"&NewLine;&Tab;&Tab; type&equals;"pubmine"&NewLine;&Tab;&Tab; data-siteid&equals;"111265417"&NewLine;&Tab;&Tab; data-section&equals;"1">&NewLine;&Tab;&Tab;<&sol;amp-ad>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;<&sol;div><p>Most available antidepressants do not help children and teenagers with serious mental health problems and some may be unsafe&comma; experts have warned&period;<&sol;p>&NewLine;<p>A review of clinical trial evidence found that of 14 antidepressant drugs only one&comma; fluoxetine – marketed as Prozac – was better than a &OpenCurlyDoubleQuote;dummy” placebo at relieving the symptoms of young people with major depression&period;<&sol;p>&NewLine;<p>The researchers conducted a systematic review of all published and unpublished trials looking at the effects of 14 antidepressants in young people with major depression up to the end of May 2015&period;<&sol;p>&NewLine;<p>Analysis of 34 trials involving 5&comma;260 participants aged nine to 18 found that only in the case of fluoxetine did benefits outweigh risks in terms of efficacy and tolerability&period;<&sol;p>&NewLine;<p>Nortriptyline was less effective than seven other drugs and placebo&comma; while imipramine&comma; venlafaxine and duloxetine were the least well tolerated&period;<&sol;p>&NewLine;<p>Compared with placebo and five other drugs&comma; venlafaxine was linked to an increased risk of suicidal attempts or thoughts&period;<&sol;p>&NewLine;<p>But the authors&comma; writing in The Lancet medical journal&comma; stressed that the true effectiveness&comma; safety and &OpenCurlyDoubleQuote;suicidility risk” of antidepressants taken by children and teenagers remained unclear because of a lack of reliable data&period;<&sol;p>&NewLine;<p>Pharmaceutical companies funded 65&percnt; of the trials and 10 were judged to have shown a high risk of bias&period; The overall quality of evidence for primary outcomes was &OpenCurlyDoubleQuote;very low”&comma; the researchers concluded&period;<&sol;p>&NewLine;<p>They recommended close monitoring of young people on antidepressants&comma; regardless of what drugs they were prescribed&comma; especially at the start of treatment&period;<&sol;p>&NewLine;<p>Major depressive disorder affects around 3&percnt; of children aged six to 12 and 6&percnt; of teenagers aged 13 to 18&period;<&sol;p>&NewLine;<p>In 2004 the US Food and Drug Administration issued a warning against the use of antidepressants in young people up to the age of 24 because of concerns about suicide risk – yet the number of young people taking the drugs increased between 2005 and 2012&period;<&sol;p>&NewLine;<p>In the UK&comma; the proportion of children and teenagers aged 19 and under taking antidepressants rose from 0&period;7&percnt; to 1&period;1&percnt;&period;<&sol;p>&NewLine;&Tab;&Tab;&Tab;<div style&equals;"padding-bottom&colon;15px&semi;" class&equals;"wordads-tag" data-slot-type&equals;"belowpost">&NewLine;&Tab;&Tab;&Tab;&Tab;<div id&equals;"atatags-dynamic-belowpost-68e30f2ca7da7">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<script type&equals;"text&sol;javascript">&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback &equals; function &lpar;&rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; false &equals;&equals;&equals; &lpar; window&period;isWatlV1 &quest;&quest; false &rpar; &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&sol;&sol; Use Aditude scripts&period;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings &equals; window&period;tudeMappings &vert;&vert; &lbrack;&rsqb;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;tudeMappings&period;push&lpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;divId&colon; 'atatags-dynamic-belowpost-68e30f2ca7da7'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;format&colon; 'belowpost'&comma;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;if &lpar; document&period;readyState &equals;&equals;&equals; 'loading' &rpar; &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;document&period;addEventListener&lpar; 'DOMContentLoaded'&comma; window&period;getAdSnippetCallback &rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub; else &lbrace;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;window&period;getAdSnippetCallback&lpar;&rpar;&semi;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;&Tab;&rcub;&NewLine;&Tab;&Tab;&Tab;&Tab;&Tab;<&sol;script>&NewLine;&Tab;&Tab;&Tab;&Tab;<&sol;div>&NewLine;&Tab;&Tab;&Tab;<&sol;div>


Discover more from London Glossy Post

Subscribe to get the latest posts sent to your email.

- Advertisement -
Exit mobile version